Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale
Mechanistic PK/PD Model: A Case Study with SGN-35
By: Dhavalkumar Shah, PhD
Senior Scientist; Modeling & Simulation, Pharmacokinetics, Dynamics, and
Metabolism; Pfizer
December 11,, 2012
12:00 to 1:00 pm EST
The presentation will lay out a step by step approach to build and validate
a novel, multiscale, mechanism-based PK/PD model for antibody drug
candidates (ADCs). The model is designed to integrate pre-clinical
biomeasures and PK/PD data to provide pre-clinical-to-clinical translation
of ADC efficacy. The presentation will highlight that it is essential to
understand and characterize the disposition of ADC and payload, at cellular
and physiological levels, to better predict the clinical outcome of ADCs.
The purpose of the "Impact" series is to foster the use of M&S activities in
all phases of drug development by illustrating the advantages and enhancing
the applicability of M&S in product discovery, development, and marketing
programs.
The series is intended for drug development project team members from
discovery to phase 4 clinical trials. This includes pharmacologists, ADME
scientists, PK/PD modelers, clinical pharmacologists, clinical development
team members, regulatory affairs specialists, and other interested
professionals.
Register for this free webinar at www.rosaandco.com/webinar. After
registering you will receive a confirmation email containing information
about joining the webinar. More information about the webinar series, an
archive of past webinars, and a list of future webinar speakers may be found
at www.rosaandco.com/webinar.
Please allow 5-10 minutes for a Java applet to be installed on your computer
prior to joining our webinar series for the first time.
Toufigh Gordi
Toufigh Gordi, PhD
President, PK/PD and Clinical Pharmacology Services
Direct: 408-480-7314
Corp: 408-370-9800
Fax: 408-370-9810
[email protected]